Biotech: Page 2


  • The Nasdaq MarketSite is seen on October 12, 2022 in New York City.
    Image attribution tooltip
    Michael M. Santiago via Getty Images

    Jounce to lay off half its workers, merge with UK biotech Redx

    The cancer biotech will combine with Redx Pharma, with the resulting company focusing on Redx’s programs for cancer and fibrotic disease.

    By Feb. 23, 2023
  • An empty laboratory
    Image attribution tooltip
    onurdongel via Getty Images

    Rubius, after layoffs and executive turnover, sets plan to dissolve

    Four years after going public with a multibillion dollar valuation, the once high-flying biotech has decided to shut down and liquidate its assets. 

    By Feb. 22, 2023
  • Colorized scanning electron micrograph of a natural killer cell from a human donor. Explore the Trendline
    Image attribution tooltip
    National Institutes of Allergy and Infectious Diseases. (2016). "Human natural killer cell" [Micrograph]. Retrieved from Flickr.
    Trendline

    Cell therapy

    Six CAR-T cell therapies are now approved in the U.S., and their continued emergence has helped fueled further research into next-generation approaches.

    By BioPharma Dive staff
  • A view of Moderna headquarters on May 08, 2020 in Cambridge, Massachusetts.
    Image attribution tooltip
    Maddie Meyer via Getty Images
    Gene editing

    Moderna inks another gene editing deal

    The messenger RNA specialist said Wednesday it is teaming up with Life Edit Therapeutics to develop therapies that can modify genes “in vivo.”

    By Feb. 22, 2023
  • A portrait of Jodie Morrison, acting CEO of Q32 Bio.
    Image attribution tooltip
    Permission granted by Atlas Venture
    Q&A // Emerging biotech

    Biotech veteran Jodie Morrison on building drug ‘platforms’ and a support group for CEOs

    There comes a time when companies with platforms need to focus on their most advanced prospects, Morrison said, rather than sink all of their funds into building the technology.

    By Feb. 21, 2023
  • A photo of a sign inside an Apellis Pharmaceuticals building
    Image attribution tooltip
    Courtesy of Apellis Pharmaceuticals

    Apellis wins FDA approval of first drug for type of vision loss

    Syfovre is the first marketed treatment for geographic atrophy, a common and irreversible eye condition. But questions linger about its benefit and safety.

    By Updated Feb. 17, 2023
  • A blurred photo of an empty laboratory
    Image attribution tooltip
    Ozankutsal via Getty Images

    Talaris restructures, ending effort to develop a cell therapy for kidney transplants

    Following a patient death and difficulty enrolling study participants, the company is laying off a third of its staff and ending a pair of studies for a two-decade-old program once owned by Novartis.

    By Feb. 16, 2023
  • A photo of Feng Zhang, founder of Aera Therapeutics, speaking with Akin Akinc, the company's CEO. Both are wearing goggles and lab coats.
    Image attribution tooltip
    Permission granted by Aera Therapeutics

    With Aera, CRISPR pioneer Feng Zhang goes after gene therapy’s delivery problem

    The company’s platform technology is built on research from Zhang’s lab at the Broad Institute, which focuses on proteins that could be used to package and deliver nucleic acids.

    By Feb. 16, 2023
  • A photo of a Biogen sign
    Image attribution tooltip
    Permission granted by Biogen

    With sales falling, Biogen’s new CEO says transformation is needed

    “There's an urgent need to restore growth to the company,” Christopher Viehbacher told investors Wednesday, on an earnings call that detailed a 7% decline in the company’s total revenue.

    By Feb. 15, 2023
  • An empty laboratory
    Image attribution tooltip
    onurdongel via Getty Images

    PureTech, tweaking research, trims a ‘small number’ of positions

    The biotech company creator is deprioritizing work on its “Orasome” drug delivery technology after what it described as a “key go/no go” experiment.

    By Feb. 14, 2023
  • Illustration of a macrophage devouring a cancer cell.
    Image attribution tooltip
    Design Cells via Getty Images

    New cancer cell therapy biotech emerges, backed by MD Anderson and Replay

    Syena will develop TCR-based natural killer cell therapies, building on research done by MD Anderson’s Katy Revzani and using technology from Replay.

    By Feb. 14, 2023
  • A photo of a building showing a GSK sign in London.
    Image attribution tooltip
    Courtesy of GSK

    GSK backs away from COVID collaboration with Vir

    The British drugmaker will retain an interest in COVID antibody drug sotrovimab, which was withdrawn from the U.S. market, and a second treatment still in early-stage trials.

    By Feb. 14, 2023
  • A photo of Halda Therapeutics and Arvinas founder Craig Crews.
    Image attribution tooltip
    Permission granted by Halda Therapeutics
    Emerging biotech

    With latest startup, repeat biotech founder Craig Crews tries to ‘hold and kill’ tumors

    Formed by the Yale scientist and Arvinas founder, Halda Therapeutics is developing a twist on targeted protein degradation, an area of research that’s recently caught drugmakers’ attention.

    By Updated Feb. 14, 2023
  • An illustration of a zoom screen with four anonymous characters situated on backdrops of DNA, dollar signs, binary code, and miscellaneous microscopic figures.
    Image attribution tooltip

    Illustration: Xavier Lalanne-Tauzia for Industry Dive

    Deep Dive // Emerging biotech

    A new generation of biotech leaders is emerging. Can they change how drug startups are built?

    Through social media, virtual meetings and mentorship programs, a growing group of entrepreneurs is looking for new ways to build drug companies.

    By Feb. 14, 2023
  • An empty laboratory
    Image attribution tooltip
    Alvarez via Getty Images

    Frequency to cut jobs after clinical trial setback

    The biotech, which has been working on drugs for hearing loss, will lay off 55% of its workforce and discontinue work on two experimental treatments.

    By Feb. 13, 2023
  • Smiling woman wearing glasses and a white lab coat engaging with other people.
    Image attribution tooltip
    Permission granted by Qiagen
    Sponsored by Qiagen

    Analyze whole genome sequencing samples at the speed of light

    Deliver fast and reliable results at low cost with a tool for whole genome analysis in just minutes

    Feb. 13, 2023
  • People walk past the Nasdaq MarketSite on October 12, 2022 in New York City.
    Image attribution tooltip
    Michael M. Santiago via Getty Images

    Another biotech IPO hits the market, as Mineralys raises $192M

    In pricing an IPO, Mineralys followed closely behind Structure Therapeutics’ offering, suggesting an opening investment window.

    By Feb. 9, 2023
  • Exterior of FDA headquarters
    Image attribution tooltip
    Courtesy of U.S. Food and Drug Administration

    FDA offers former biotech unicorn Intarcia a chance for a panel review

    Intarcia, which once held a multibillion-dollar valuation, deflated following the FDA’s 2017 and 2020 rejections of its drug-device combination for diabetes.

    By Feb. 9, 2023
  • Idorsia shares sink on ‘unexpected’ failure of drug study

    The Actelion spinout’s drug clazosentan, which is approved for use in Japan, didn’t significantly outperform a placebo in a Phase 3 study of patients with a particular type of stroke.

    By Feb. 6, 2023
  • An illustration of red blood cells.
    Image attribution tooltip
    Pixelimage via Getty Images

    Magenta to explore sale, merger after study setback

    The biotech recently stopped a trial of its experimental conditioning regimen over safety concerns. Now it’s halting further development work as it undertakes a strategic review.

    By Feb. 3, 2023
  • A photograph of an empty laboratory.
    Image attribution tooltip
    gorodenkoff via Getty Images

    COVID-19 vaccine maker Medicago to close down

    The company, which worked with GSK to develop a coronavirus shot, is ceasing operations after its corporate parent cut off further investment. 

    By Feb. 3, 2023
  • The exterior of the Nasdaq MarketSite in New York City.
    Image attribution tooltip
    Michael M. Santiago via Getty Images

    Biotech startup Structure pulls off rare IPO, raising $161M

    Structure, which is developing a competitor to marketed diabetes and obesity drugs from Novo Nordisk and Eli Lilly, had one of the strongest Wall Street debuts for a new company since 2021.

    By Feb. 2, 2023
  • An empty laboratory
    Image attribution tooltip
    Alvarez via Getty Images

    3 more biotechs announce layoffs as industry cost-cutting continues

    Evelo Biosciences, Quince Therapeutics and Inovio are the latest to pare down workforces in the face of clinical setbacks and depressed stock prices.

    By Feb. 1, 2023
  • Business person examines a binder with data.
    Image attribution tooltip
    Charnchai via Getty Images
    Emerging biotech

    Biotech CFOs eye research cuts, partnerships amid sector retrenchment: report

    The report, a yearly poll of 100 financing executives by accounting and consulting firm BDO, revealed the many levers young drugmakers are pulling to conserve cash.

    By Jan. 30, 2023
  • An empty laboratory
    Image attribution tooltip
    Alvarez via Getty Images

    Celularity warns of layoffs for ‘substantial portion’ of its staff

    After a strategic review, the Celgene spinout said it won’t advance two experimental cancer therapies that use “natural killer” cells.

    By Jan. 27, 2023
  • Veteran biotech leader George Scangos to step down as Vir CEO

    The former Biogen head is retiring after taking Vir from a small startup to a publicly traded developer of infectious disease drugs. Bayer executive Marianne De Backer will succeed him.

    By Jan. 25, 2023